# US 2021/0275636 A1 · COMPOSITIONS CONTAINING EXOSOME CARRYING NF-kB INHIBITORS AND METHODS OF USING THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275636 A1
- Document ID: US20210275636A1
- Status: Published application
- Kind: A1
- Application number: 17/138,864
- Filed: 2020-12-30
- Published: 2021-09-09
- Earliest claimed: 2019-12-30
- Assignees: Ilias Biologics Inc.; Ilias Therapeutics, Inc.; Korea Advanced Institute of Science and Technology
- Applicants: ILIAS Biologics Inc; ILIAS Therapeutics, Inc.; Korea Advanced Institute of Science and Technology
- Inventors: Chulhee CHOI; Kyungsun CHOI; Ramkumar MENON
- Web page: https://patentgrep.com/patent/US20210275636A1

## CPC

- A61K 38/1738: {Calcium binding proteins, e.g. calmodulin}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 38/164: {from bacteria}
- A61K 38/168: {from plants}
- A61K 38/1709: {from mammals}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/45: Transferases (2)
- A61K 38/51: Lyases (4)
- A61K 47/6911: {the form being a liposome}
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

## Claims

### Claim 1

A method for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in maternal and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in maternal and/or fetus comprising:
administering a composition comprising extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor; and a photo-specific binding protein,
to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the extracellular vesicles are exosomes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the photo-specific binding protein is a first photo-specific binding protein or a second photo-specific binding protein.

### Claim 4 (depends on 3)

The method of claim 3, wherein the first photo-specific binding protein is conjugated to an exosome specific marker to form a first fusion protein (fusion protein I); and the second photo-specific binding protein is conjugated to the NF-κB inhibitory protein to form a second fusion protein (fusion protein II).

### Claim 5 (depends on 3)

The method of claim 3, wherein the fusion protein I and the fusion protein II are linked reversibly through the first photo-specific binding protein and the second photo-specific binding protein.

### Claim 6 (depends on 4)

The method of claim 4, wherein the first photo-specific binding protein is conjugated to the exosome specific marker to be located in the direction toward inside of the exosome.

### Claim 7 (depends on 3)

The method of claim 3, wherein the first photo-specific binding protein and the second photo-specific binding protein are selected from the group consisting of cryptochrome-interacting basic-helix-loop-helix protein (CIB), N terminal domain of CIB (CIBN), phytochrome B (PhyB), phytochrome interacting factor (PIF), Flavin binding, Kelch repeat F-box 1 (FKF1), GIGANTEA, CRY2 cryptochrome 2 (CRY2) and photolyase-homologous region (PHR).

### Claim 8 (depends on 3)

The method of claim 3, wherein the first photo-specific binding protein is CIB or CIBN and the second photo-specific binding protein is CRY2 or PHR, or the first photo-specific binding protein is CRY2 or PHR and the second photo-specific binding protein is CIB or CIBN.

### Claim 9 (depends on 3)

The method of claim 3, wherein the first photo-specific binding protein is PhyB and the second photo-specific binding protein is PIF or the first photo-specific binding protein is PIF and the second photo-specific binding protein is PhyB.

### Claim 10 (depends on 3)

The method of claim 3, wherein the first photo-specific binding protein is GIGANTEA and the second photo-specific binding protein is FKF1 or the first photo-specific binding protein is FKF1 and the second photo-specific binding protein is GIGANTEA.

### Claim 11 (depends on 4)

The exosome of claim 4, wherein the exosome specific marker is selected from the group consisting of CD9, CD63, CD81 and CD82.

### Claim 12 (depends on 1)

The method of claim 1, wherein the NF-κB inhibitor is selected from the group consisting of a NF-κB inhibiting drug, a NF-κB inhibitory protein or fragment thereof, and a mixture thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the NF-κB inhibitory protein is selected from the group consisting of IκB, super repressor-IκB (srIκB), IκB-α, IκB-β, IκB-ε and B cell lymphoma 3 (BCL3), a mutant thereof and a mixture thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition is administered via oral, transdermal, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, vaginal, intrauterine route, or a mixture thereof.

### Claim 15 (depends on 1)

The method of claim 1, further comprising:
administering an antibiotic or a uterine contraction inhibitor with, before or after the administration of the composition of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antibiotic is selected from the group consisting of penicillin, cephalosporins, macrolides, lincosamide, carbapenems, glycopeptides, aminoglycosides, tetracyclines, erythromycin, nitroimidazoles, β-lactamase inhibitors, a derivative thereof, and a mixture thereof; and the uterine contraction inhibitor is selected from the group consisting of progesterone, nifedipine, atosiban, ritodrine, indomethacin, magnesium sulfate, orciprenaline, terbutaline, salbutamol, fenoterol, nylidrin, isoxsuprine, hexoprenaline, and a mixture thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the condition related to inflammation in uterus and/or fetus during pregnancy is selected from the group consisting of prenatal inflammatory response, prenatal labor, preterm delivery, preterm rupture of amniotic membrane, low birth weight, adenomyosis, fetal inflammatory response syndrome (FIRS), uterine fibroid, intrauterine inflammation, chorioamnionitis, amnionitis, amniotic fluid infection, placental infection, and intraamniotic infection (Intra-amniotic infection), and a mixture thereof.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the condition related to inflammation in uterus and/or fetus during pregnancy is selected from the group consisting of prenatal inflammatory response, prenatal labor, preterm delivery, preterm rupture of amniotic membrane, low birth weight, adenomyosis, fetal inflammatory response syndrome (FIRS), uterine fibroid, and a mixture thereof.

### Claim 19 (depends on 18)

The use of claim 18, wherein the condition related to inflammation in uterus and/or fetus during pregnancy is selected from the group consisting of prenatal inflammatory response, prenatal labor, preterm delivery, preterm rupture of amniotic membrane, low birth weight, adenomyosis, fetal inflammatory response syndrome (FIRS), uterine fibroid, and a mixture thereof.
